- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04991454
Xenon MRI Pulm Hypertension (Jupiter PH)
Xenon MRI in Pulmonary Hypertension
Study Overview
Status
Intervention / Treatment
Detailed Description
In aim 1, the study team will compare 129Xe MRI signatures to lung explant pathology, cellular identity from single-cell RNA sequencing, and cellular phenotypes in gas exchange defects to areas that are spared, which the team will hypothesize are exposed to lower levels of hemodynamic shear stress. This will be done by performing 129Xe MRI scans in fifteen subjects (cohort 1) with PAH awaiting a lung transplant, followed by a pathologic assessment (with usual histopathology and single cell RNA sequencing) of the subject's explanted lung after transplant. The study team expect that areas of proliferation and fibrosis will correlate with 129Xe MRI gas exchange and spectroscopic defects
In aim 3, The study team will test whether directly monitoring lung pathology with 129Xe MRI will provide additional prognostic information to standard-of-care clinical monitoring in 45 subjects (cohort 2). At 6-month follow-up appointments, standard-of-care assessments including labs, echocardiography, and six-minute walk distance and 129Xe MRI will be collected. The study team expect that In aim 1, the study team will compare 129Xe MRI signatures to lung explant pathology, cellular identity from single-cell RNA sequencing, and cellular phenotypes in gas exchange defects to areas that are spared, which the study team hypothesizes are exposed to lower levels of hemodynamic shear stress. This will be done by performing 129Xe MRI scans in fifteen subjects (cohort 1) with PAH awaiting a lung transplant, followed by a pathologic assessment (with usual histopathology and single-cell RNA sequencing) of the subject's explanted lung after transplant. The study team expect that areas of proliferation and fibrosis will correlate with 129Xe MRI gas exchange and spectroscopic defects
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: David Ptashnik, MS
- Phone Number: 919-668-2642
- Email: david.ptashnik@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University Medical Center
-
Contact:
- David Ptashnik
- Phone Number: 919-668-2642
- Email: david.ptashnik@duke.edu
-
Principal Investigator:
- Sudarshan Rajagopal, MD
-
Sub-Investigator:
- Bastiann Driehays, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria of Cohort 1
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- Outpatients of either gender, Age 18-75
- Awaiting a lung transplant
- Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, pulmonary vascular resistance ≥ 3 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH), 3 (PH due to chronic lung disease, 4 (PH due to pulmonary artery obstructions), or 5 (PH due to miscellaneous causes)
- Willing and giving informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).
- Women of childbearing potential must have a negative urine pregnancy test before MRI
Exclusion Criteria of Cohort 1
Subjects presenting with any of the following will not be included in the trials:
- Moderate to severe heart disease (LVEF <45%, Severe LV hypertrophy, Moderate to severe valvular disease)
- PH due to schistosomiasis
- Active cancer
- Sickle cell anemia
- Prisoners and pregnant women will not be approached for the study
- Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine)
- Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
Inclusion Criteria of Cohort 2
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- Treatment naïve or treatment started within the last 3 months
- Outpatients of either gender, Age 18-75
- WHO functional class (FC) 2-3 symptoms with a diagnosis of group 1 PH (mean pulmonary artery pressures (mPAP) > 20 mmHg, pulmonary capillary wedge pressure (PCWP) ≤ 15mmHg and pulmonary vascular resistance (PVR) ≥3 WU)
- Willing and able to give informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).
- Women of childbearing potential must have a negative urine pregnancy test before MRI
Exclusion Criteria of Cohort 2
Subjects presenting with any of the following will not be included in the trials:
- Sarcoidosis
- Active cancer
- Sickle cell anemia
- Liver disease (Childs-Pugh class C)
- Any conditions that prevent the performance of 129Xe MRI scans.
- Prisoners and pregnant women will not be approached for the study.
- Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine).
- Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: end-stage pulmonary hypertension .
subjects with end-stage PH that currently on the waitlist for lung transplant
|
Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.
|
Other: following pulmonary arterial hypertension subjects
Following pulmonary arterial hypertension subjects upto 24 months
|
Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pulmonary vascular remodeling
Time Frame: 5 years
|
The study team will determine whether the correlation between Red Blood Cell Signal from Xenon MRI to pathologic scoring of pulmonary vascular remodeling from histopathology is statistically significant.
|
5 years
|
Red Blood Cell Signal from Xenon MRI
Time Frame: 5 years
|
We will determine whether the correlation between Red Blood Cell Signal from Xenon MRI to six minute walk distance, tricuspid annular plane excursion and right ventricular systolic pressure in longitudinal follow-up of PAH patients is statistically significant.
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sudarshan Rajagopal, MD, PhD, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00107613
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on 129Xe Hyperpolarized
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; Children... and other collaboratorsRecruitingInterstitial Lung DiseasesUnited States
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Ontario Lung Association; Cyclomedica Australia...Enrolling by invitation
-
Bastiaan DriehuysMerck Sharp & Dohme LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary HypertensionUnited States
-
McMaster UniversitySt. Joseph's Healthcare HamiltonRecruitingBronchiectasis | Chronic Obstructive Pulmonary Disease | Asthma | Emphysema | Pulmonary Fibrosis | Alpha 1-Antitrypsin Deficiency | Bronchopulmonary Dysplasia | Sarcoidosis, PulmonaryCanada
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)TerminatedChronic Obstructive Pulmonary DiseaseUnited States
-
Bastiaan DriehuysAmerican Heart AssociationNot yet recruitingConnective Tissue Diseases | Pulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)United States
-
Bastiaan DriehuysRecruitingPulmonary Arterial Hypertension | Interstitial Lung Disease | COPDUnited States
-
Bastiaan DriehuysCompleted
-
Xemed LLCChildren's Hospital of PhiladelphiaNot yet recruiting
-
University of Kansas Medical CenterActive, not recruiting